Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL397819 | 0.87 | PTGDR2 (0.78) | PTGDR2 | |
| SCHEMBL10074104 | 0.81 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL438227 | 0.81 | PTGDR2 (0.74) | PTGDR2 | |
| SCHEMBL1939869 | 0.74 | PTGDR2 (0.85) | PTGDR2 | |
| SCHEMBL1222480 | 0.74 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL400776 | 0.70 | PTGDR2 (0.78) | PTGDR2 | |
| SCHEMBL463206 | 0.68 | PTGDR2 (0.74) | PTGDR2 | |
| SCHEMBL1939755 | 0.66 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL6527650 | 0.65 | PTGDR2 (0.86) | PTGDR2 | |
| SCHEMBL6025989 | 0.65 | PTGDR2 (0.78) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017209272-A1 | CANCER METASTASIS INHIBITOR | 国立大学法人東京大学 | 2017-12-07 | — | — | WO | disclosed |
| WO-2017104728-A1 | MEDICINE FOR TREATING FOOD ALLERGY | 国立大学法人東京大学 | 2017-06-22 | — | — | WO | disclosed |
| US-8101645-B2 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | ABBOTT LABORATORIES (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101645-B2 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | ABBOTT LABORATORIES (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101645-B2 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | ABBOTT LABORATORIES (US) | 2012-01-24 | — | — | US | disclosed |
| US-20090209609-A1 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | ABBVIE INC. | 2009-08-20 | — | — | US | disclosed |
| WO-2009102462-A1 | THIENOPYRROLES AND PYRROLOTHIAZOLES AS NEW THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2009-08-20 | — | — | WO | disclosed |
| US-20090209609-A1 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | ABBVIE INC. | 2009-08-20 | — | — | US | disclosed |
| US-20090209609-A1 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | ABBVIE INC. | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209609-A1 | Thienopyrroles and pyrrolothiazoles as new therapeutic agents | HRH2, HRH1, TSLP | PTGDR2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.